💋
send ‘💋’ if your muse thinks mine is kissable.
Maverick couldn't help but feel a surge of excitement and anticipation as Aya admitted that he looked kissable. Her words sparked a playful response within him, even though he was her boss, and the boundaries of their professional relationship were at play.
Maverick feigned shock, "oh, Aya, my dear employee. You've caught me off guard with such a scandalous statement! What will the others think? The CEO kissing his employee? Scandalous indeed!"
He maintained the playful tone, masking his true emotions beneath the surface. Maverick's gaze lingered on Aya's lips, his mind racing with thoughts of crossing the line between professional and personal. It's just not possible to deny the newfound attraction that had blossomed within him.
With both sincerity and desire, he leaned closer and added, "But maybe... just maybe, Aya, the opinions of others matter less than the connection we share. You already know- I've always admired your work, your dedication, and your spirit. And now, I find myself drawn to you in ways I never anticipated."
He reached out, gently brushing a strand of hair away from Aya's face, his gaze locked with hers. Now he told her in a softer tone, "Aya, there's something between us, something beyond our professional roles. I want to try, I want to explore it, to see where it leads us. If you're open to it, I'd like to embark on a new chapter together, where our connection can thrive both inside and outside the office."
He knew the risks involved, the potential consequences of pursuing a romantic relationship with an employee, but the pull towards Aya was too strong to ignore. He smiled at her warmly before asking, "so, Aya, what do you say? Shall we take a leap of faith and discover what lies beyond the boundaries of our work life?"
@ayakoito
28 notes
·
View notes
Biopharmaceutics
3 notes
·
View notes
if i ever grow another braincell i’ll talk about vought and the image crafting of not allowing supes to be seen in anything but their suits & the complex around human vs supe/gods among men it creates by portraying supes as regular people (homelander’s fake home/backstory, the ad in season 1, a-train’s ‘biopic’ film) but only showing their humanity while keeping them dressed up.
7 notes
·
View notes
Europe Biopharmaceutical PEC Market to reach $25.02 billion by 2030
Meticulous Research®– a leading global market research company, published a research report titled, “Europe Biopharmaceutical Processing Equipment and Consumables Market by Product Type {Filtration, Chromatography [Consumables, Equipment], Disposable Bioreactors, Cell Culture Media, Shakers, Services), Application (Vaccine, mAb, R&D), and End User - Forecast to 2030.”
According to this latest publication from Meticulous Research, the Europe biopharmaceutical processing equipment and consumables market is expected to grow at a CAGR of 9.7% to reach $25.02 billion by 2030. The growth of this market is driven by factors such as the growth of the biopharmaceuticals market, capacity expansions of biopharmaceutical plants, and the growing adoption of single-use bioprocessing equipment. However, biopharmaceuticals' complex development and manufacturing process restrain the market’s growth.
To gain more insights into the market with a detailed table of content and figures, click here: https://www.meticulousresearch.com/product/europe-biopharmaceutical-processing-equipment-and-consumables-market-5551
Furthermore, the shift towards Bioprocessing 4.0 and the rising adoption of personalized medicine are expected to offer significant market growth opportunities. The intensive capital requirements for biopharmaceutical production pose a major challenge to the market’s growth. The use of disposable processing equipment for commercial production and the rising focus on continuous bioprocessing are prevailing trends in the Europe biopharmaceutical processing equipment and consumables market.
Europe Biopharmaceutical Processing Equipment and Consumables Market Market: Future Outlook
The Europe Biopharmaceutical Processing Equipment and Consumables Market is segmented based on Product Type [Filtration Systems, Chromatography Equipment and Consumables (Consumables, Equipment), Bioreactors (Reusable Bioreactors, Disposable/Single-use Bioreactors), Cell Culture Products (Cell Culture Media {Cell Culture Media, by Physical Form [Dry Powder Media, Liquid Media], Cell Culture Media, by Type [Off-the-Shelf Media, Custom Media], Cell Culture Media, by Source [Chemically Defined Media, Natural Media]}, Reagents and Supplements, Cell and Cell Lines, Serum), Mixing Systems, Bioprocessing Containers (BPC), Sterilizers, Centrifuges, Incubators, Shakers, Biosafety Cabinets, Other Equipment and Consumables, Service], Application [Commercial Bioproduction, Vaccine Manufacturing, (Monoclonal Antibody Production, Recombinant Protein Production, Cell and Gene Therapy), Research Bioproduction], End User [Pharmaceutical and Biopharmaceutical Companies, Contract Development Manufacturing Organizations (CDMOs), Academia and Research Institutes].
Download Sample Report Here- https://www.meticulousresearch.com/download-sample-report/cp_id=5551
Among the product types, in 2023, the filtration systems segment is expected to account for the largest share of the Europe biopharmaceutical processing equipment and consumables market. The biopharmaceutical industry needs different filtration methods depending on what sort of solution is being used. Filtration is commonly employed in bioprocesses to remove undesirable particles like cell debris from cultures, viruses, and other bacteria. The largest share of this segment is attributed to the increasing demand for innovative filtration and separation techniques owing to the increasing production of biotherapeutic molecules.
Among the applications, the commercial bioproduction segment is projected to grow at the highest CAGR over the forecast period. The large market share of this segment can be attributed to the growing consumption of biopharmaceutical equipment and consumables in commercial production and the growing demand for biopharmaceutical products.
Among the end users, in 2023, the pharmaceutical and biopharmaceutical companies segment is expected to account for the largest share of the Europe Biopharmaceutical Processing Equipment and Consumables market. The pharmaceutical and biopharmaceutical companies have witnessed significant growth in recent years. The large market share of this segment can be attributed to the increasing demand for biopharmaceutical products and the growing adoption of single-use products. Furthermore, government initiatives and capacity expansion by biopharmaceutical manufacturing companies contribute to this segment's largest share.
Request for Sample: https://www.meticulousresearch.com/request-sample-report/cp_id=5551
Geographic Review
This research report analyzes countries and provides a comprehensive analysis of European countries Germany, France, the U.K., Italy, Switzerland, Spain, Ireland, Denmark, Belgium, and the Rest of Europe. In 2023, Germany is expected to account for the largest share of the Europe biopharmaceutical processing equipment and consumables market. The increase in pharmaceutical export, government grants, and funding to biotech and biopharmaceutical companies drives the growth of this market. For instance, in 2020, BioNTech SE (Germany), a biotech company, received funding of USD 424 million (EUR 375 million) from the German Federal Ministry of Education and Research to support the development of mRNA-based COVID-19 vaccines.
Key Players
The key players profiled in the Europe biopharmaceutical processing equipment and consumables market report are Sartorius AG (Germany), Merck KGaA (Germany), Eppendorf AG (Germany), Solaris Biotechnology Srl (Italy), Thermo Fisher Scientific Inc. (U.S.), 3M Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Agilent Technologies, Inc (U.S.), Repligen Corporation (U.S.), and Danaher Corporation (U.S.).
Quick Buy: https://www.meticulousresearch.com/Checkout/77176576
Key questions answered in the report-
Which are the high-growth market segments in terms of product type, application, end user, and countries?
What was the historical market for Europe biopharmaceutical processing equipment and consumables across the globe?
What are the market forecasts and estimates for the period 2023–2030?
What are the major drivers, restraints, challenges, opportunities, and trends in the Europe biopharmaceutical processing equipment and consumables market?
Who are the major players in the Europe biopharmaceutical processing equipment and consumables market?
What is the competitive landscape, and who are the market leaders in the Europe biopharmaceutical processing equipment and consumables market?
What are the recent developments in the Europe biopharmaceutical processing equipment and consumables market?
What are the different strategies adopted by the major players in the Europe biopharmaceutical processing equipment and consumables market?
What are the geographical trends and high-growth countries?
Contact Us:
Meticulous Research®
Email-
[email protected]
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
0 notes
According to the latest research by nova one advisor, the global biopharmaceuticals contract manufacturing market size was exhibited at USD 19.89 billion in 2023 and is projected to hit around USD 31.92 billion by 2032, growing at a CAGR of 5.4% during the forecast period 2023 to 2032.
0 notes
Products are getting better and better. How do you think?
1 note
·
View note
Unleash the Potential of Your Biopharmaceuticals: Expert Consulting Services
Quantum Pharmatech Services - Your trusted partner in biopharmaceutical consulting. We provide a comprehensive suite of services to support you throughout the entire drug development lifecycle. Our team of industry offers unparalleled expertise in navigating regulatory hurdles, optimizing processes, and ensuring the highest quality standards. Contact us today for a free consultation and unlock the full potential of your biopharmaceutical endeavors.
0 notes
Biopharmaceutical Processing Equipment and Consumables Market Analysis, Size, Share, and Forecast 2031
0 notes
The Evolving Landscape of Healthcare Cold Chain Logistics in 2024
The healthcare cold chain logistics market is booming, driven by the need for efficient and sustainable transportation of temperature-sensitive medical products
The Booming Landscape of Healthcare Cold Chain Logistics
The healthcare industry relies heavily on the secure and efficient transportation of temperature-sensitive medical products. This intricate network is known as the healthcare cold chain logistics market, expected to reach a staggering USD 23.65 billion by 2030 at a CAGR of 7.89%.
Market Segmentation: A Multifaceted Approach
The market…
View On WordPress
0 notes
@ayakoito in his private chambers (based on X)
The air was filled with a mix of nervous excitement and a sense of forbidden desire, knowing that their relationship was kept secret from the world. He lit a few scented candles to create a cozy, intimate ambiance. The soft flickers of candlelight danced across the room, casting gentle shadows against the walls. The crackling fire in the stone hearth added a touch of warmth and comfort to the space in the city penthouse, its gentle glow reflecting in Maverick's eyes as he adjusted the logs.
"Aya," he murmured, his voice laced with a mixture of longing and affection. "Being here with you, it feels like a dream come true. You have no idea how much you mean to me."
His fingers caressed her cheek, tracing a delicate path along her jawline as he continued, his voice filled with sincerity. "Every stolen moment we've shared, every touch, every stolen kiss—it's etched into my heart. You ignite a fire in me, a passion that burns brighter than anything I've ever known."
18 notes
·
View notes
Powder compression, the primary technique for tablets manufacturing, involves applying pressure to force particles together in a confined space, creating a porous, solid specimen with defined geometry. This process occurs within a die using upper and lower punches to apply compressive force, resulting in a reduction in volume and the formation of bonds between particles. As a result, a compact, coherent tablet is produced.
The article:
1 note
·
View note
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
Pittsburgh, PA, April 05, 2024 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that its abstract has been accepted for the 2024 American Society of Clinical Oncology (ASCO) meeting on May 31 through June 4 in Chicago, Illinois. Lipella’s abstract, “Intravesical local administration of pembrolizumab for treatment of bladder cancer: A novel strategy to minimize toxicity” will be published at www.asco.org/abstracts.
Dr. Jonathan Kaufman, Chief Executive Officer of Lipella, said, “ASCO’s 2024 meeting is the ideal venue for dissemination of our recent progress in the treatment of bladder cancer. Lipella’s new product candidate, LP-50 (intravesical pembrolizumab), is intended to be indicated for non-muscle invasive bladder cancer (NMIBC). Our abstract includes preclinical data demonstrating the efficacy of intravesical pembrolizumab in mice, including size-reduction in bladder tumors measured via T2 weighted MRI.”
ASCO is the world's leading professional organization for physicians and oncology professionals caring for people with cancer. Its annual meeting is the most significant gathering of oncology professionals worldwide, and aims to change the landscape of cancer care.
Dr. Michael Chancellor, Lipella’s Chief Medical Officer, emphasized the significance of this milestone for advancing the company’s LP-50 program. He stated, “There exists a critical unmet need for patients with non-muscle invasive bladder cancer. Our proprietary liposomal drug delivery technology enables localized delivery of therapeutics such as pembrolizumab, which can have severe adverse effects when absorbed systemically.”
About LP-50
LP-50 is an intravesical formulation of immunoglobulins including local, intravesical PD-1 (i.e. checkpoint) inhibition, intended for the treatment of non-muscle invasive bladder cancer (NMIBC), offering the potential for increasing efficacy while minimizing systemic toxicity.
About Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Additionally, Lipella maintains a therapeutic focus on diseases with significant, unaddressed morbidity and mortality where no approved drug therapy currently exists. Lipella completed its initial public offering in December 2022. For more information, please visit www.lipella.com or LinkedIn.
Forward-Looking Statements
This press release includes certain "forward-looking statements." All statements, other than statements of historical fact, included in this press release regarding, among other things, our strategy, future operations, financial position, prospects, clinical trials, regulatory approvals, pipeline and opportunities, sources of growth, successful implementation of our proprietary technology, plans and objectives are forward-looking statements. Forward-looking statements can be identified by words such as "may," "will," "could," "continue," "would," "should," "potential," "target," "goal," "anticipates," "intends," "plans," "seeks," "believes," "estimates," "predicts," "expects," "projects" and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding future events and financial trends that we believe may affect among other things, market and other conditions, our financial condition, results of operations, business strategy, short- and long-term business operations and objectives, and financial needs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you, therefore, against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. There are risks, uncertainties and other factors, both known and unknown, that could cause actual results to differ materially from those in the forward-looking statements which include, but are not limited to, risks related to the effective application of the use of proceeds from the private placement, general capital market risks, regional, national or global political, economic, business, competitive, market and regulatory conditions, and other factors. Any forward-looking statement made by us is based upon the reasonable judgment of our management at the time such statement is made and speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. In addition, the information contained in this press release is as of the date hereof, and the Company has no obligation to update such information, including in the event that such information becomes inaccurate. You should not construe the contents of this press release as legal, tax and financial advisors as to legal and related matters concerning the matters described herein.
CONTACT
Dr. Jonathan Kaufman, CEO
Lipella Pharmaceuticals
[email protected]
1-412-894-1853
SOURCE: Lipella Pharmaceuticals Inc
0 notes
According to the latest research by nova one advisor, the global biopharmaceuticals contract manufacturing market size was exhibited at USD 19.89 billion in 2023 and is projected to hit around USD 31.92 billion by 2032, growing at a CAGR of 5.4% during the forecast period 2023 to 2032.
0 notes
The Biopharmaceutical Processing Equipment and Consumables Market is expected to grow at a CAGR of 10.3% from 2022 to 2029 to reach $70.84 billion by 2029. Biopharmaceutical processing involves the study of discovery, development, and processing of complex medicines using living cells and organisms. Biopharmaceuticals include vaccines, whole blood and blood components, gene therapies, recombinant therapeutic proteins, gene therapies, and somatic cells.
0 notes